Compare GAB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | STOK |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | GAB | STOK |
|---|---|---|
| Price | $6.00 | $32.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 667.8K | ★ 930.2K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $47.31 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $4.56 | $5.35 |
| 52 Week High | $5.88 | $38.69 |
| Indicator | GAB | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 58.88 |
| Support Level | $6.15 | $32.26 |
| Resistance Level | $6.29 | $35.43 |
| Average True Range (ATR) | 0.06 | 2.12 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 7.81 | 62.78 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.